Literature DB >> 12667138

Evidence for the interaction of the hereditary haemochromatosis protein, HFE, with the transferrin receptor in endocytic compartments.

Paige S Davies1, An-Sheng Zhang, Emily L Anderson, Cindy N Roy, Michael A Lampson, Timothy E McGraw, Caroline A Enns.   

Abstract

HFE, the protein mutated in hereditary haemochromatosis type 1, is known to interact with the transferrin receptor (TfR) on the cell surface and during endocytosis [Gross, Irrinki, Feder and Enns (1998) J. Biol. Chem. 273, 22068-22074; Roy, Penny, Feder and Enns (1999) J. Biol. Chem. 274, 9022-9028]. However, whether they are capable of interacting with each other once inside the cell is not known. In the present study we present several lines of evidence that they do interact in endosome compartments. Cells expressing a chimaera of HFE protein with the cytoplasmic domain of lysosomal-associated membrane protein 1 (LAMP1) in place of its own (HFE-LAMP) show a decrease in the half-life of the TfR. This implies that the interaction between HFE and TfR in endosomes targets the TfR to lysosomal compartments. The interaction between TfR and HFE-LAMP was confirmed by immunoprecipitation, in addition to immunofluorescence studies. Addition of transferrin (Tf) to HFE-LAMP-expressing cells competes with HFE for binding to the TfR, thereby increasing the half-life of TfR and confirming that the HFE-LAMP-TfR complex reaches the cell surface prior to entering the endosomal vesicles and trafficking to the lysosome. These results raise the possibility that interaction of HFE and TfR in intracellular vesicles may play an important role in determining the function of HFE in iron homoeostasis, which is still unknown. Analysis of endosomal pH and the iron content of internalized Tf indicated that HFE does not appear to alter the unloading of iron from Tf in the endosome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667138      PMCID: PMC1223471          DOI: 10.1042/BJ20030202

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  Interactions of the ectodomain of HFE with the transferrin receptor are critical for iron homeostasis in cells.

Authors:  C N Roy; E J Carlson; E L Anderson; A Basava; S M Starnes; J N Feder; C A Enns
Journal:  FEBS Lett       Date:  2000-11-10       Impact factor: 4.124

2.  Molecular modeling of human serum transferrin for rationalizing the changes in its physicochemical properties induced by iron binding. Implication of the mechanism of binding to its receptor.

Authors:  H Yajima; T Sakajiri; T Kikuchi; M Morita; T Ishii
Journal:  J Protein Chem       Date:  2000-04

3.  Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells.

Authors:  Cindy N Roy; Kenneth P Blemings; Kathryn M Deck; Paige S Davies; Emily L Anderson; Richard S Eisenstein; Caroline A Enns
Journal:  J Cell Physiol       Date:  2002-02       Impact factor: 6.384

4.  Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites.

Authors:  A P West; A M Giannetti; A B Herr; M J Bennett; J S Nangiana; J R Pierce; L P Weiner; P M Snow; P J Bjorkman
Journal:  J Mol Biol       Date:  2001-10-19       Impact factor: 5.469

5.  The detection of four molecular forms of human transferrin during the iron binding process.

Authors:  D G Makey; U S Seal
Journal:  Biochim Biophys Acta       Date:  1976-11-26

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells.

Authors:  H D Riedel; M U Muckenthaler; S G Gehrke; I Mohr; K Brennan; T Herrmann; B A Fitscher; M W Hentze; W Stremmel
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

8.  The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor.

Authors:  J A Lebrón; A P West; P J Bjorkman
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

9.  Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis.

Authors:  S V Ben-Arieh; B Zimerman; N I Smorodinsky; M Yaacubovicz; C Schechter; I Bacik; J Gibbs; J R Bennink; J W Yewdell; J E Coligan; H Firat; F Lemonnier; R Ehrlich
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype.

Authors:  B Corsi; S Levi; A Cozzi; A Corti; D Altimare; A Albertini; P Arosio
Journal:  FEBS Lett       Date:  1999-10-22       Impact factor: 4.124

View more
  6 in total

Review 1.  Molecular insights into the pathogenesis of hereditary haemochromatosis.

Authors:  A Pietrangelo
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 2.  A general map of iron metabolism and tissue-specific subnetworks.

Authors:  Valerie Hower; Pedro Mendes; Frank M Torti; Reinhard Laubenbacher; Steven Akman; Vladmir Shulaev; Suzy V Torti
Journal:  Mol Biosyst       Date:  2009-03-06

3.  The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor.

Authors:  Lior Horonchik; Marianne Wessling-Resnick
Journal:  Chem Biol       Date:  2008-07-21

4.  Processing of hemojuvelin requires retrograde trafficking to the Golgi in HepG2 cells.

Authors:  Julia E Maxson; Caroline A Enns; An-Sheng Zhang
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

5.  Transferrin receptor-mediated internalization and intracellular fate of conjugates of a DNA aptamer.

Authors:  Nan Zhang; Junyan Wang; Tao Bing; Xiangjun Liu; Dihua Shangguan
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-12       Impact factor: 8.886

6.  The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells.

Authors:  Bahire Kucukkaya; Demet Erdag; Fahri Akbas; Leman Yalcintepe
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.